These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37459124)

  • 21. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
    Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
    J Clin Invest; 2006 Jan; 116(1):193-201. PubMed ID: 16341263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.
    Kaufer D; Gandy S
    Neurology; 2009 Dec; 73(24):2052-3. PubMed ID: 19923549
    [No Abstract]   [Full Text] [Related]  

  • 24. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
    Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul S
    Autoimmun Rev; 2008 May; 7(5):391-7. PubMed ID: 18486927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
    Wang J; Hara H; Makifuchi T; Tabira T
    J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to the amyloid beta-protein.
    Bancher C; Grundke-Iqbal I; Iqbal K; Kim KS; Wisniewski HM
    Neurobiol Aging; 1989; 10(2):125-32. PubMed ID: 2657463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disaggregation of Alzheimer beta-amyloid by site-directed mAb.
    Solomon B; Koppel R; Frankel D; Hanan-Aharon E
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4109-12. PubMed ID: 9108113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    Gandy S; Ehrlich ME
    N Engl J Med; 2023 Jan; 388(1):80-81. PubMed ID: 36599066
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.
    Lee EB; Leng LZ; Zhang B; Kwong L; Trojanowski JQ; Abel T; Lee VM
    J Biol Chem; 2006 Feb; 281(7):4292-9. PubMed ID: 16361260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system.
    Stern RA; Otvos L; Trojanowski JQ; Lee VM
    Am J Pathol; 1989 May; 134(5):973-8. PubMed ID: 2524164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformation-specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen.
    Bonito-Oliva A; Schedin-Weiss S; Younesi SS; Tiiman A; Adura C; Paknejad N; Brendel M; Romin Y; Parchem RJ; Graff C; Vukojević V; Tjernberg LO; Terenius L; Winblad B; Sakmar TP; Graham WV
    J Cell Mol Med; 2019 Mar; 23(3):2103-2114. PubMed ID: 30663210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.
    Crespi GA; Hermans SJ; Parker MW; Miles LA
    Sci Rep; 2015 Apr; 5():9649. PubMed ID: 25880481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.
    Morales-Corraliza J; Schmidt SD; Mazzella MJ; Berger JD; Wilson DA; Wesson DW; Jucker M; Levy E; Nixon RA; Mathews PM
    Neurobiol Aging; 2013 Jan; 34(1):137-45. PubMed ID: 22608241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of amyloid antibodies for Alzheimer disease - immunotherapy.
    Huwait EA; Baghallab IM; Glabe CG; Abulnaja KO; Kumosani TA; Moselhy SS
    Arch Physiol Biochem; 2022 Oct; 128(5):1275-1282. PubMed ID: 32449861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects.
    Kozin SA; Barykin EP; Mitkevich VA; Makarov AA
    Biochemistry (Mosc); 2018 Sep; 83(9):1057-1067. PubMed ID: 30472944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood.
    Stern RA; Trojanowski JQ; Lee VM
    FEBS Lett; 1990 May; 264(1):43-7. PubMed ID: 1692541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.